Genomenon Unveils Groundbreaking Genomic Knowledgebase Powered by AI
/in Artificial Intelligence/by MaxDinuclear Platinum(II) Complexes: A Promising New Chemotherapy to Treating Prostate Cancer
/in Chemotherapy, Preclinical Research/by MaxNewsletter 5
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Here I am with the fifth newsletter from the site. I hope I will be like Santa Prostate and bring you some exciting discovery by Christmas! We also have a podcast if you prefer to listen to the newsletter, you can find it […]
Hijacking the Brakes: Scientists Uncover Prostate Cancer’s Growth Secret
/in CRISPR, Preclinical Research/by MaxDietary Intervention Shows Promise in Slowing Prostate Cancer Progression
/in Clinical Trial, Localized/by MaxInvikafusp Alfa: New Hope for Advanced, Anti-PD-1 Resistant Cancers Phase 1 and 2 Trial
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA New Hope for Hard-to-Treat Cancers: a New TACC3 Inhibitor
/in Clinical Trial, Not PCa related/by MaxTiny Robots Revolutionize Targeted Drug Delivery: Caltech’s Microscopic Marvels
/in Delivery, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- ARASEC Trial Validates Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer May 16, 2026
- Telmisartan: A Familiar Blood Pressure Pill with New Potential in Cancer Therapy May 15, 2026
- Targeted Alpha Therapy Plus PARP Blockade: AZD2265 plus AZD9574 for Advanced Prostate Cancer May 15, 2026
- Phase 1 Trial: GTB-5550, Another B7-H3 NK-targeted Therapy for mCRPC May 15, 2026